decor

Bextra and Celebrex Settlement

Seeger Weiss played a major role in securing $894 million in settlements for people who took arthritis medications Bextra or Celebrex and experienced heart complications. Drug injuries caused by the medications also resulted in withdrawal of Bextra from the market and prompted the FDA to require serious “black box warnings” regarding cardiovascular risk on Celebrex.

Sign up for our newsletter to get updates on drugs & medical devices

If you would like to sign up for our newsletter click the button below.

Sign Up For Newsletter

$894 Million Dangerous Drug Settlement

In 2008, Pfizer announced plans to pay $894 million to settle claims over drug injuries caused by its arthritis medications, Bextra and Celebrex. The settlement included $745 million for personal injury claims, $60 million to settle improper marketing claims with several states and $89 million to settle class action lawsuits for consumer fraud related to promotional materials.

In September 2009, Pfizer also agreed to pay $2.3 billion to settle a U.S. Department of Justice investigation regarding the marketing of Bextra and other Pfizer drugs. Additionally, in 2016, Pfizer announced a settlement of $486 million for shareholders who claimed that the company had concealed the risks of Bextra, resulting in financial losses for its stock.

Due to the high rate of drug injuries, Bextra was withdrawn from the market only a few months after its approval and the U.S. Food and Drug Administration began requiring “black box warnings” on Celebrex due to a risk of cardiac events.

Sign up for our newsletter here.

Enter your email to get updates from Drugdangers

We value your privacy. By submitting, you agree to our privacy policy and disclaimer. After submitting, you will be contacted by one of DrugDanger’s trusted legal partners. This is legal advertising.

Sign up to keep up to date with accurate law news.

2024 Drug Dangers.com

All rights reserved

NOTICE: This website, the related links, and the social media accounts of Seeger Weiss contain Attorney Advertising. No aspect of this or any advertisement has been approved by the Supreme Court of New Jersey. Seeger Weiss’ websites and social media accounts are designed for general information only. The information contained on Seeger Weiss’ websites and social media accounts should not be construed as legal advice, should not be relied upon as a substitute for the retention of an attorney or for independent legal research, and does not create an attorney-client relationship. The materials presented by this website are not medical advice, and are not a substitute for the opinion of a qualified healthcare professional. Seeger Weiss LLP routinely represents clients for alleged personal injuries, including injuries sustained due to use of prescription drugs and medical devices. Do not stop taking a prescribed medication or stop using a prescribed medical device without first consulting with your doctor. Discontinuing a prescribed medication or use of a prescribed medical device without your doctor’s advice can result in injury or death. Notwithstanding claims relating to certain drugs and medical devices, the drug or medical device may remain approved by the U.S. FDA. An endorsement of the firm or report of prior results does not guarantee or predict a similar outcome with respect to any future matter. Firm only practices law where permitted through proper admission, licensure or court approval. This ad is limited to specific litigation, not general legal services, and is not intended to solicit legal representation that would constitute the unauthorized practice of law in any jurisdiction. Provision of information as to your experience does not create an attorney-client relationship, no attorney-client relationship is formed until execution of a retainer agreement.

↑